A single-site, phase 1, double-blind, safety and immunogenicity trial of an alphavirus replicon vaccine expressing cytomegalovirus genes (AVX601) in healthy volunteers

Trial Profile

A single-site, phase 1, double-blind, safety and immunogenicity trial of an alphavirus replicon vaccine expressing cytomegalovirus genes (AVX601) in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2008

At a glance

  • Drugs AVX 601 (Primary) ; AVX 601 (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors AlphaVax
  • Most Recent Events

    • 07 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
    • 25 Oct 2008 Interim results presented at ICAAC/IDSA 2008.
    • 17 Apr 2008 Preliminary results reported in an AlphaVax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top